Immutep
Search :
Corporate Information
Product Development
Clinical Trials
Business Strategy
Investor Relations
Contact Us
News
February 4, 2012
Topics:
Corporate Information
Product Development
Clinical Trials
Business Strategy
Investor Relations
Contact Us
News
>
Page bottom
Home
»
News
»
First Funding
First Funding
IMMUTEP closes funding to develop novel therapeutic vaccines. Click to read the complete
Press Release
(PDF Format).
Published 04/2004 by
admin@immutep.com
© 2002 Immutep, S.A.
Press Release
01/2011 -
Immutep and GlaxoSmithKline sign licence agreement for IMP731, a novel therapeutic antibody for the treatment of autoimmune diseases
Immutep S.A. announced today the execution of a licence agreement ...
09/2010 -
Immutep announces final results in phase I/II chemoimmunotherapy trial in metastatic breast cancer.
Clinical research paper describes IMP321’s potency in achieving ...
05/2010 -
Immutep Announces Oral Presentation at ASCO Annual Meeting of IMP321 Final Results In Phase I/II Chemoimmunotherapy Trial
Immutep S.A. announced today that the final results from its Phase ...
01/2010 -
Interview Frederic Triebel with PharmaTelevision
01/2010 -
ImmuFact IMP321 doubles clinical response rate in first-line metastatic breast cancer
Immutep S.A. announced today the final results from its Phase I/II ...